Five criteria to use when selecting a CRO for a gene therapy study
9 Jan 2023With cell and gene therapies (CGT) quickly making their way from theory to clinical practice, many biopharmaceutical companies are looking for CRO partners with significant experience conducting CGT-focused clinical studies. In this white paper, QPS describes five criteria to consider when evaluating organizations.
Related Products
Request Quote for All Products
QPS Clinical Phase I/IIa Development Services
QPSMoving quickly and safely through Phase I/IIa trials is critical to successful drug development. The QPS Phase I research facilities feature more than 550 beds across six strategically located facilities on three continents. QPS is well known for its success in first-in-human clinical trials. All Phase I sites are staffed by expert clinical pharmacology teams that routinely conduct hundreds of phase I/IIa studies annually.
QPS Global Regulatory Affairs Services
QPSQPS Global Custom-Built Regulatory Services Can Transform Clinical Trials. QPS Global Regulatory Affairs (GRA) service offerings focus on helping pharmaceutical, biotechnology, and medical device companies to develop custom-built research solutions that forge expedited regulatory pathways from discovery to global commercialization and onwards through product lifecycle support.